E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Polycystic ovarian syndrome and/or thyroid autoimmunity in combination with an euploid pregnancy loss |
Polycystisk ovaiesyndrom og/eller thyroideaautoimmunitet i kombination med et graviditetstab af et euploidt foster |
|
E.1.1.1 | Medical condition in easily understood language |
Polycystic ovarian syndrome and/or antibodies against the thyroid gland in combination with a pregnancy loss of a featus where the chromosome analysis was normal |
Polycystisk ovaiesyndrom og/eller antistoffer mod skjoldbruskkirtlen i kombination med et graviditetstab af et foster med normalt antal kromosomer |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Female diseases of the urinary and reproductive systems and pregancy complications [C13] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10065161 |
E.1.2 | Term | Polycystic ovarian syndrome |
E.1.2 | System Organ Class | 100000004872 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 21.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10069094 |
E.1.2 | Term | Thyroid peroxidase antibody positive |
E.1.2 | System Organ Class | 100000004848 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10060326 |
E.1.2 | Term | Thyroglobulin antibody positive |
E.1.2 | System Organ Class | 100000004848 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 22.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10072314 |
E.1.2 | Term | Pregnancy loss |
E.1.2 | System Organ Class | 100000004868 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To test if immune modulation with low-dose tacrolimus can increase live birth rate in women with euploid PL and a diagnosis of PCOS and/or thyroid autoimmunity. |
Målet er at teste, om behandling med en lav dosis af tacrolimus gennem hele graviditeten øger chancen for et levendefødt barn blandt kvinder med PCOS og/eller thyroidea autoimmunitet og et tidligere graviditetstab af et euploidt foster. |
|
E.2.2 | Secondary objectives of the trial |
Not applicable |
Not applicable |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Females diagnosed with Polycystic ovarian syndrome and/or thyroid autoimmunity in combination with an euploid pregnancy loss. Furthermore, the woman should actively want to achieve pregnancy again. |
Kvinder diagnosticeret med polycystisk ovaiesyndrom og/eller thyroideaautoimmunitet i kombination med et graviditetstab af et euploidt foster. Derudover skal kvinden ønske at opnå graviditet inden for den nærmeste fremtid. |
|
E.4 | Principal exclusion criteria |
Age under 18 years old, Severe uterine malformation. Known balanced maternal or paternal chromosomal abnormality, diagnosed with HIV, Hepatitis B or C, Currently treatment with immunmodulating medicine, kidney failure, previously treated with tacrolimus during pregnancy, previously participated in the study |
Alder < 18 år, betydende uterine anomalier, balancerede kromosomanomalier hos en af forældrene, diagnosticeret med HIV, hepatitis B eller C , fast behandling med immunmodulerende medicin såsom systemisk binyrebarkhormon, svær nyreinsufficiens , tidligere behandlet med tacrolimus i forbindelse med graviditet, tidligere deltagelse i forsøget
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary endpoint is an increase in live birth of 15% resulting in a live birth rate of 76% in the tacrolimus group |
Primære endpoint er at øge chancerne for et levendefødt barn med 15% hos gruppen der behandles med tacrolimus. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
The primary end point will be evaluated after the last included female has given birth, or had a pregnancy loss |
Det primære end point vil blive evalueret efter den sidste inkluderede kvinde har født, eller har haft et graviditetstab. |
|
E.5.2 | Secondary end point(s) |
Secondary end points are: Ongoing pregnancy at the 4 follow-up visits during pregnancy. Ploidi status of a pregnancy loss during the clinical trial, the incidence of extrauterine pregnancies, chromosome analysis in fetuses where pregnancy is terminated, Finally, obstetric and perinatal complications in the two allocation groups are compared by monitoring birth weight, gestational age at birth (or at pregnancy loss), delivery method, Apgar score after 1 and after 5 minutes, and admission to and duration at neonatal intensive care unit. Post-partum thyroiditis rate, Thyroid peroxidase antibody (TPOAbs) and Thyroglobulin antibody (TgAbs) concentration, thyroid status, PCOS related biochemical status, Thyroid-Related Patient-Reported Outcome score (THYPRO), Perceived Stress Scale score (PSS) and Major Depression Inventory score (MDI). |
De sekundære end points er raten af ongoing graviditeter ved de 4 follow-up besøg. Ploidistatus af graviditetstab som sker under forsøget registreres. Forekomsten af ekstrauterine graviditeter. Kromosomanalyse hos fostre, hvor graviditeten afbrydes. Endelig sammenlignes obstetriske og perinatale komplikationer i de to allokeringsgrupper ved monitorering af fødselsvægt, gestationsalder ved fødsel (eller ved fostertab), fødselsforløb, Apgar score efter 1. og efter 5 minutter, samt indlæggelse og indlæggelsesvarighed. Post-partum thyroiditis rate, TPOAbs og TgAbs koncentrationen, thyroidea status, PCOS relateret biokemisk status, Thyroid-Related Patient-Reported Outcome score (THYPRO), Perceived Stress Scale score (PSS) og Major Depression Inventory score (MDI).
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
The secondary end points will be evaluated after the last included female has been to the last follow up visit 12 weeks after giving birth or after a pregnancy loss
|
De sekundære endpoints vil blive evalueret efter den sidste inkluderede kvinde har været til sidste follow-up besøg 12 uger efter fødslen, eller efter et graviditetstab |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 6 |